of this Annual Report on Form 10-K. The process required by the FDA before drugs may be marketed in the U.S. generally involves the following: completion of non-clinical laboratory tests, animal studies and formulation studies conducted according to good laboratory practice or other applicable regulations; submission of an IND, which must become effective before human clinical trials may be initiated; 15 adequate and well-controlled human clinical trials to establish the safety and efficacy of t...
Q2 FY2026 — expected 2026-08-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001193125-26-046876 | EDGAR | 87K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027824 | EDGAR | — |
| 2024-02-07 | 2023-12-31 | 0000950170-24-012322 | EDGAR | — |
| 2023-02-10 | 2022-12-31 | 0001564590-23-001685 | EDGAR | — |
| 2022-02-09 | 2021-12-31 | 0001564590-22-004429 | EDGAR | — |
| 2021-02-17 | 2020-12-31 | 0001564590-21-006406 | EDGAR | — |
| 2020-02-26 | 2019-12-31 | 0001564590-20-006766 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001564590-19-007584 | EDGAR | — |
| 2018-03-07 | 2017-12-31 | 0001564590-18-004757 | EDGAR | — |
| 2017-03-21 | 2016-12-31 | 0001564590-17-004911 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-29 | 2026-06-30 | 0001193125-26-324219 | EDGAR | — |
| 2025-10-23 | 2025-09-30 | 0001193125-25-247059 | EDGAR | 57K words |
| 2025-07-23 | 2025-06-30 | 0000950170-25-097950 | EDGAR | — |
| 2025-04-24 | 2025-03-31 | 0000950170-25-058129 | EDGAR | — |
| 2024-10-23 | 2024-09-30 | 0000950170-24-116708 | EDGAR | — |
| 2024-07-24 | 2024-06-30 | 0000950170-24-086111 | EDGAR | — |
| 2024-04-25 | 2024-03-31 | 0000950170-24-047833 | EDGAR | — |
| 2023-10-25 | 2023-09-30 | 0000950170-23-055259 | EDGAR | — |
| 2023-07-26 | 2023-06-30 | 0000950170-23-034773 | EDGAR | — |
| 2023-04-26 | 2023-03-31 | 0000950170-23-014883 | EDGAR | — |
| 2022-10-26 | 2022-09-30 | 0001564590-22-035295 | EDGAR | — |
| 2022-07-27 | 2022-06-30 | 0001564590-22-026717 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-29 | 0001193125-26-323652 | EDGAR | — |
| 2026-02-11 | 0001193125-26-046536 | EDGAR | 5K words |
| 2025-10-22 | 0001193125-25-246775 | EDGAR | — |
| 2025-08-19 | 0001607678-25-000003 | EDGAR | — |
| 2025-07-23 | 0000950170-25-097885 | EDGAR | — |
| 2025-05-27 | 0000950170-25-077865 | EDGAR | — |
| 2025-04-23 | 0000950170-25-057337 | EDGAR | — |
| 2025-04-23 | 0000950170-25-057323 | EDGAR | — |
| 2025-03-11 | 0000950170-25-036820 | EDGAR | — |
| 2025-02-05 | 0000950170-25-014464 | EDGAR | — |
198 total filings indexed. 166 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001607678 |
| Ticker | VKTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.vikingtherapeutics.com |
| Listed | 2015-04-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VKTX (~200 tokens, structured JSON with cryptographic provenance)